HLscience Co., Ltd.
Financials
Valuation Metrics
HLscience Co., Ltd.'s Market Cap is ₩285B. At end of 2025 it was ₩436B. Ranked #2124 of 2,421 in KR market (top 88%), #1367 of 1,640 on KOSDAQ (top 83%), #45 of 57 in Household & Personal Products (top 79%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 28.47B KRW | KR#2,124/2,421 Sec#45/57 |
| Revenue | 10.44B KRW | KR#2,286/2,421 Sec#53/57 |
| Net Income | -11.22B KRW | KR—/2,421 Sec—/57 |
| Total Assets | 85.04B KRW | KR#1,903/2,421 Sec#41/57 |
| Net Assets | 82.77B KRW | KR#1,560/2,421 Sec#32/57 |
| Employees | 84 | KR#1,779/2,421 Sec#42/57 |
| Value | ||
| P/B | 0.34x | KR#427/2,421 Sec#8/57 |
| P/S | 2.73x | KR#1,949/2,421 Sec#51/57 |
| FCF Yield | -26.38% | KR—/2,421 Sec—/57 |
| Profitability | ||
| ROE | -13.55% | KR#1,998/2,421 Sec#46/57 |
| ROA | -13.19% | KR#2,161/2,421 Sec#52/57 |
| Op. Margin | -96.28% | KR#2,298/2,421 Sec#56/57 |
| Revenue Growth | -42.45% | KR#2,271/2,421 Sec#55/57 |
| Financial Health | ||
| Debt Ratio | 2.75% | KR#12/2,421 Sec#2/57 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/57 |
| FCF | -7.51B KRW | KR#1,615/2,421 Sec#45/57 |
| Cash | 1.78B KRW | KR#2,266/2,421 Sec#53/57 |
| Current Ratio | 14.74x | KR#51/2,421 Sec#2/57 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/57 |
| Performance | ||
| 1Y Return | -52.39% | KR#2,094/2,421 Sec#47/57 |
| 1M Return | 1.34% | KR#1,085/2,421 Sec#21/57 |
| From 52W High | -54.99% | KR#1,650/2,421 Sec#43/57 |
| 1Y MDD | -55.74% | KR#1,248/2,421 Sec#36/57 |
| Trading | ||
| Volume | 161 shares | KR#2,373/2,421 Sec#56/57 |
| Trading Value | 846,310 KRW | KR#2,376/2,421 Sec#56/57 |
| Foreign Own. | 0.83% | KR#2,092/2,421 Sec#44/57 |
| Per Share | ||
| EPS | -2,080 KRW | KR—/2,421 Sec—/57 |
| BPS | 15,350 KRW | KR#687/2,421 Sec#14/57 |
Company Info
HL Science, originally Geongang Sarang, was founded in 2000 and listed on KOSDAQ in 2016. In 2022, it completed Korea's first Ministry of Food and Drug Safety-approved individually recognized raw material CDMO smart factory in Chungju, Chungcheongbuk-do. The company operates as a technology platform enterprise, focusing on research into new biomaterials and new technologies for bio healthcare, encompassing R&D, manufacturing, and sales. It has developed 12 individually recognized raw materials, securing 48 domestic and international patent registrations and 16 patent applications, establishing an integrated Value Chain system. Headquartered in Uiwang, Gyeonggi-do.